MedTrace Logo

Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence

NCT01769781 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2016-04-27

No results posted yet for this study

Summary

The aromatase inhibitor (anastrazole) plus long acting GnRH agonist leuprolide acetate will be tested for the treatment of women with endometriosis recurrence compared with classical GnRH analog treatment. Pain symptom disappearance and disease free time during follow-up will be the outcomes for establishing which medical treatment is the best in endometriosis recurrence treatment.

Conditions

  • Endometriosis

Interventions

DRUG

anastrazole

combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months

DRUG

GnRH analog alone

treatment for three months with GnRH analog (leuprolide acetate) alone

Sponsors & Collaborators

  • Centre for Endocrinology and Reproductive Medicine, Italy

    lead NETWORK

Principal Investigators

  • marco sbracia, md · CERM-HUNGARIA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01769781 on ClinicalTrials.gov